Clinical trials in diffuse large B cell lymphoma

The table below shows a list of The Lymphoma Group's current clinical trials open/due to open for recruitment for Diffuse large B-cell lymphoma patients.

To find out how you can access one of these clinical trials or to contact us with a question, see our page 'How to be referred'.

For an explanation on the different phases of trials click here.

 

 

Trial Name

 

Description

 

Click the link for more information (external page)

 

ACCEPT

 

A phase 1b/2 study of acalabrutinib with R-CHOP chemotherapy

Suitable for patients who haven’t yet received any treatment

 

 

 

ADCT-402-101

 

A Phase 1 study evaluating the new drug ADCT-402.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

BI 1206 CRUK CD32b

 

Phase 1/2a study looking at blocking the CD32b protein with the antibody BI 1206.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

C34004

 

Phase 2 Study of TAK-659 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

GILEAD 1757

 

Phase 1b study of the selective BTK inhibitor ONO/GS-4059.

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

IELSG37

 

A phase 3 study to find out if radiotherapy can be safely omitted in people with primary mediastinal large B-cell lymphoma who are PET negative after chemotherapy.

Suitable for patients who haven't yet received any treatment.

 

 

 

INCA

 

Phase 2 trial comparing inotuzumab ozogamicin and gemcitabine with R-CVP in patients unsuitable for R-CHOP.

Suitable for patients who haven’t yet received any treatment.

 

 

 

INCYTE (CITADEL-202)

 

A phase 2 trial testing a new drug, INCB050465

Suitable for patients with lymphoma which has come back after previous treatment.

 

 

 

JAVELIN DLBCL

 

A phase 1/3 trial testing a new drug avelumab.

Suitable for patients with lymphoma which has come back after previous treatment.

 

 

 

LYMRIT 37 05

 

Phase 1 study of the antibody Betalutin® which targets the CD37 antigen.

Suitable for patients with lymphoma which has come back after previous treatment.

 

 

 

MEDI4736 (FUSION)

 

Phase 1/2 study to assess the safety and tolerability of durvalumab, the anti-pd-l1 antibody.

Suitable for patients with lymphoma which has come back after previous treatment.

 

 

 

PCYC-1123

 

Phase 1b/2 study of ibrutinib, lenalidomide and rituxumab

Suitable for patients with lymphoma which has come back after previous treatment

 

 

 

TAK659

 

Phase 1 first in human study of the inhibitor TAK-659

Suitable for patients with lymphoma that has come back after treatment

 

 

 

MaPLe

 

Non-medicinal (observational) study involving molecular profiling on patients with suspected or confirmed DLBCL or grade 3b follicular lymphoma

 

 

 

*Please note, we update this page fortnightly

 

With special thanks to the following:

;